Government Directs Manufacturers to Reduce MRP of Anticancer Drugs Following Tax Cuts

New Delhi: Manufacturers have started to reduce the maximum retail price (MRP) on three anticancer drugs — Trastuzumab Deruxtecan, Osimertinib, and Durvalumab drugs — as directed by the government to pass on the benefits to the consumers, the Parliament was informed on Friday. 

The government had issued notifications to reduce basic customs duty (BCD) to zero on these three drugs/formulations, apart from slashing GST rates on these anticancer drugs from 12 per cent to 5 per cent, Union Minister of State for Chemicals and Fertilisers, Anupriya Patel, told the Lok Sabha in a written reply.

She said that in compliance with the notifications, manufacturers reduced the MRP on these drugs and filed the information with the National Pharmaceutical Pricing Authority (NPPA).

The NPPA had issued a memorandum, directing the companies to reduce MRP on these drugs on account of reduction in GST rates and exemption from customs duties, so as to pass on the benefit of reduced taxes and duties to the consumers and to furnish information about change in prices. (IANS)

Also Read: PM Narendra Modi and Bhutan King Discuss Enhanced Economic Connectivity

Also Watch: